Statistics of heart failure and mechanical circulatory support in 2020

Abstract

Heart failure is increasing in prevalence, with approximately 26 million patients affected worldwide. This represents a significant cause of morbidity and mortality. Statistics regarding heart failure patient age, hospitalization likelihood, and mortality differ significantly by country. Heart failure patients are typically classified by ejection fraction, with distinct phenotypes associated with reduced ejection fraction (rEF) or preserved ejection fraction (pEF). Heart failure has a significant financial impact related to hospitalization, medication, and procedural expenses. The costs of heart failure also extend to the reduced quality of life conferred by heart failure symptoms. Management of heart failure includes a variety of interventions, including mechanical circulatory support (MCS). MCS, including left ventricular assist devices (LVADs), right ventricular assist devices (RVADs) and extracorporeal membrane oxygenation (ECMO),has been a means of managing end stage heart failure. Given the relative scarcity of transplant organs, the utilization of MCS, particularly as a bridge to transplantation (BTT) has grown significantly. In this review, we discuss statistics related to heart failure and MCS. We evaluate how patients are classified and examine global trends and regional differences. We then address MCS therapies, the costs associated with heart failure, the impact of heart failure on patient quality of life, and data regarding morbidity and mortality.

Prediction of all-cause mortality with malnutrition assessed by controlling nutritional status score in patients with heart failure: a systematic review and meta-analysis

“…Heart failure remains a growing public health burden (1) . Despite advancements in medical care, heart failure is still the main cause of mortality, morbidity and hospital readmission (2) .…”

Анализ ЭКГ При Моделировании Хронической Сердечной Недостаточности У Крыс И Курсовом Введении Нового Потенциального Препарата «Гипертрил»

“…After metoprolol administration the duration of repolarization was more than 40 % higher than that in intact rats and untreated animals with CHF, and it was 50 % of the RR cardiac cycle duration. The duration of electrical diastole TR, although it Фармакологія та лікарська токсикологія, Том (1), 20-30 increased 2 times compared with animals with CHF, but it remained 5 times shorter than in intact animals. After Hypertril administration the ECG showed normalization of the amplitude of the ventricular R wave and normalization of the amplitude of the T repolarization wave, a significant decrease in the amplitude of the ST segment above the isoline -4 times compared with the control group and 2,5 times compared with animals treated with metoprolol, normalization of the duration of the QRS complex and the T wave, as well as the TR interval.…”

“…Хроническая сердечная недостаточ ность (ХСН) -одна из ключевых с клинической и экономической точки зрения проблем для систем здраво охранения большинства развитых стран мира, которую отличает широ кая распространенность и неблагопри ятный прогноз [1]. Общая смертность при ХСН в зависимости от тяжести заболевания варьирует в пределах от 15 до 50 %, причем ежегодная смерт ность больных III и IV функциональ ного класса (ФК) достигает 40 % и свыше 60 % соответственно, а показа тели внезапной смертности состав ляют 50 % и более от общей [2].…”

Engineering Cardiovascular Tissue Chips for Disease Modeling and Drug Screening Applications

“…Heart failure is one of the most prominent CVDs (Virani et al, 2021) with limited strategies for surgical intervention (Bowen et al, 2020). To model heart failure using tissue chips, a gas chamber and a bioreactor were employed to recapitulate the mechanical cues of cardiac fibrosis using cardiac fibroblasts (Kong et al, 2019).…”